[go: up one dir, main page]

DK1373259T3 - Pyridazinonaldosereduktaseinhibitorer - Google Patents

Pyridazinonaldosereduktaseinhibitorer

Info

Publication number
DK1373259T3
DK1373259T3 DK02716247T DK02716247T DK1373259T3 DK 1373259 T3 DK1373259 T3 DK 1373259T3 DK 02716247 T DK02716247 T DK 02716247T DK 02716247 T DK02716247 T DK 02716247T DK 1373259 T3 DK1373259 T3 DK 1373259T3
Authority
DK
Denmark
Prior art keywords
pyridazinonal
reductase inhibitors
dose
dose reductase
inhibitors
Prior art date
Application number
DK02716247T
Other languages
Danish (da)
English (en)
Inventor
Banavara Lakshman Mylari
Original Assignee
Pfizer Prod Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer Prod Inc filed Critical Pfizer Prod Inc
Application granted granted Critical
Publication of DK1373259T3 publication Critical patent/DK1373259T3/da

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/12—Antidiuretics, e.g. drugs for diabetes insipidus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D307/00—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
    • C07D307/77—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom ortho- or peri-condensed with carbocyclic rings or ring systems
    • C07D307/78—Benzo [b] furans; Hydrogenated benzo [b] furans
    • C07D307/82—Benzo [b] furans; Hydrogenated benzo [b] furans with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to carbon atoms of the hetero ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
    • C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D495/04—Ortho-condensed systems

Landscapes

  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Diabetes (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Endocrinology (AREA)
  • Emergency Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
DK02716247T 2001-03-30 2002-01-31 Pyridazinonaldosereduktaseinhibitorer DK1373259T3 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US28005101P 2001-03-30 2001-03-30
PCT/IB2002/000320 WO2002079198A1 (en) 2001-03-30 2002-01-31 Pyridazinone aldose reductase inhibitors

Publications (1)

Publication Number Publication Date
DK1373259T3 true DK1373259T3 (da) 2005-03-29

Family

ID=23071435

Family Applications (2)

Application Number Title Priority Date Filing Date
DK02716247T DK1373259T3 (da) 2001-03-30 2002-01-31 Pyridazinonaldosereduktaseinhibitorer
DK04023149T DK1491540T3 (da) 2001-03-30 2002-01-31 Intermediater, der er anvendelige til syntese af pyridazinon-aldosereduktase inhibitorer

Family Applications After (1)

Application Number Title Priority Date Filing Date
DK04023149T DK1491540T3 (da) 2001-03-30 2002-01-31 Intermediater, der er anvendelige til syntese af pyridazinon-aldosereduktase inhibitorer

Country Status (43)

Country Link
US (2) US6579879B2 (es)
EP (3) EP1491540B1 (es)
JP (1) JP2004528319A (es)
KR (1) KR100586138B1 (es)
CN (1) CN1215067C (es)
AP (1) AP2002002461A0 (es)
AR (1) AR035798A1 (es)
AT (3) ATE348100T1 (es)
AU (1) AU2002226634B2 (es)
BG (1) BG108179A (es)
BR (1) BR0208571A (es)
CA (1) CA2442476A1 (es)
CZ (1) CZ20032563A3 (es)
DE (3) DE60217930T2 (es)
DK (2) DK1373259T3 (es)
EA (1) EA006023B1 (es)
EC (1) ECSP034671A (es)
EE (1) EE200300470A (es)
ES (2) ES2274369T3 (es)
GE (1) GEP20053675B (es)
HR (1) HRP20030752A2 (es)
HU (1) HUP0303644A3 (es)
IL (1) IL156462A0 (es)
IS (3) IS2205B (es)
MA (1) MA27003A1 (es)
MX (1) MXPA03008850A (es)
MY (1) MY134304A (es)
NO (1) NO20034345L (es)
NZ (1) NZ528406A (es)
OA (1) OA12453A (es)
PA (1) PA8541801A1 (es)
PE (1) PE20030007A1 (es)
PL (1) PL365294A1 (es)
PT (2) PT1373259E (es)
SI (1) SI1373259T1 (es)
SK (1) SK11852003A3 (es)
TN (1) TNSN02037A1 (es)
TW (1) TWI245762B (es)
UA (1) UA73236C2 (es)
UY (1) UY27237A1 (es)
WO (1) WO2002079198A1 (es)
YU (1) YU71403A (es)
ZA (1) ZA200304671B (es)

Families Citing this family (43)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU714980B2 (en) 1996-07-24 2000-01-13 Warner-Lambert Company Llc Isobutylgaba and its derivatives for the treatment of pain
ES2240657T3 (es) * 2001-02-28 2005-10-16 Pfizer Products Inc. Compuestos de sulfonilpiridazinona utiles como inhibidores de aldosa reductasa.
YU71403A (sh) * 2001-03-30 2006-05-25 Pfizer Products Inc. Piridazinoni kao inhibitori aldoza reduktaze
AU761191B2 (en) * 2001-05-24 2003-05-29 Pfizer Products Inc. Therapies for tissue damage resulting from ischemia
CN1269814C (zh) 2002-01-09 2006-08-16 辉瑞产品公司 哒嗪酮抗糖尿病药的制备方法和中间体
US20040092522A1 (en) * 2002-08-15 2004-05-13 Field Mark John Synergistic combinations
US7419981B2 (en) * 2002-08-15 2008-09-02 Pfizer Inc. Synergistic combinations of an alpha-2-delta ligand and a cGMP phosphodieterse 5 inhibitor
US6872833B2 (en) * 2003-04-14 2005-03-29 Hoffmann-La Roche Inc. Adenosine receptor ligands
US8017634B2 (en) 2003-12-29 2011-09-13 President And Fellows Of Harvard College Compositions for treating obesity and insulin resistance disorders
US7262318B2 (en) * 2004-03-10 2007-08-28 Pfizer, Inc. Substituted heteroaryl- and phenylsulfamoyl compounds
AR049384A1 (es) 2004-05-24 2006-07-26 Glaxo Group Ltd Derivados de purina
EP1750862B1 (en) 2004-06-04 2011-01-05 Teva Pharmaceutical Industries Ltd. Pharmaceutical composition containing irbesartan
US20050288340A1 (en) * 2004-06-29 2005-12-29 Pfizer Inc Substituted heteroaryl- and phenylsulfamoyl compounds
EP1769088A2 (en) * 2004-06-30 2007-04-04 Whitehead Institute For Biomedical Research Novel methods for high-throughput genome-wide location analysis
GB0514809D0 (en) 2005-07-19 2005-08-24 Glaxo Group Ltd Compounds
US7741317B2 (en) 2005-10-21 2010-06-22 Bristol-Myers Squibb Company LXR modulators
US7888376B2 (en) 2005-11-23 2011-02-15 Bristol-Myers Squibb Company Heterocyclic CETP inhibitors
BRPI0706523A2 (pt) * 2006-01-13 2011-01-04 Wyeth Corp composto de fórmula i; composição farmacêutica; método de tratamento de distúrbios que estão relacionados com ou são afetados pela inibição da recaptação de norepinefrina, o receptor de 5-ht6 ou o receptor de 5-ht2a; método de tratamento de um distúrbio de aprendizado, de um distúrbio cognitivo, de um distúrbio de memória, de um distúrbio de personalidade, de um distúrbio comportamental, de um distúrbio de movimento, de um distúrbio neurodegenerativo, de abstinência de droga, de distúrbio de sono, de um distúrbio alimentar, de uma toxicidade de droga aguda, de um distúrbio cardiovascular, de uma disfunção sexual, de um distúrbio gastrintestinal, de um distúrbio genitourinário, de um distúrbio de dor, de um distúrbio nervoso ou de um distúrbio de sintoma vasomotor; método de tratamento de doença de alzheimer, de um distúrbio de deficiência da atenção, de esquizofrenia, de doença de parkinson, de discinésia tardia, de ataxia, de bradicinésia, de discinésias paroxìsmicas, de sìndrome da perna irrequieta, de tremor, de tremor essencial, de epilepsia, de apoplexia ou de trauma na cabeça; método de tratamento de doença arterial coronariana, de enfarte do miocárdio, de ataque isquêmico transitório, de angina, de fibrilação atrial, de agregação plaquetária, de risco de formação de coágulo sanguìneo, de sìndrome do intestino irritável, de constipação crÈnica, de doença do refluxo gastrintestinal, de dispepsia, de incontinência urinária por estresse ou de incontinência urinária de urgência; método de tratamento de depressão, de distúrbio compulsivo obsessivo, de tendência ao suicìdio, de distúrbio de ansiedade, de distúrbio bipolar, de distúrbio de pánico, de abstinência de nicotina, de abstinência de álcool, de abstinência de cocaìna, de abstinência de heroìna, de abstinência de anfetamina, de abstinência de drogas narcóticas, de insÈnia, de apnéia do sono, de narcolepsia, de distúrbio afetivo sanzonal, de sìndrome da perna irrequieta, de distúrbio de sono de turno de trabalho, de sìndrome da fase do sono retardada, de anorexia nervosa, de bulimia nervosa, de sìndrome do comer noturno, de superalimentação compulsiva, de sìndrome da fadiga crÈnica, de fibromialgia, de neuropatia de dor, de dor antinociceptiva, de sìndrome da dor crÈnica, de neuropatia diabética, de fogacho ou de suor noturno; e uso de um composto
CA2838448A1 (en) 2006-06-27 2008-01-03 Takeda Pharmaceutical Company Limited Fused cyclic compounds
ATE547394T1 (de) 2006-12-01 2012-03-15 Bristol Myers Squibb Co N-((3-benzyl)-2,2-(bis-phenyl)-propan-1- aminderivate als cetp-hemmer für die behandlung von atherosklerose und herz-kreislauf- erkrankungen
US8173645B2 (en) * 2007-03-21 2012-05-08 Takeda San Diego, Inc. Glucokinase activators
SG157299A1 (en) 2008-05-09 2009-12-29 Agency Science Tech & Res Diagnosis and treatment of kawasaki disease
CA2783699C (en) 2009-12-08 2019-01-15 Case Western Reserve University Primary amine compounds for treating ocular disorders
US8916563B2 (en) 2010-07-16 2014-12-23 The Trustees Of Columbia University In The City Of New York Aldose reductase inhibitors and uses thereof
CN104080451B (zh) * 2011-09-15 2016-08-24 台北医学大学 吲哚异羟肟酸和吲哚啉异羟肟酸于治疗心脏衰竭或神经损伤的用途
US9339542B2 (en) * 2013-04-16 2016-05-17 John L Couvaras Hypertension reducing composition
MX2015014666A (es) 2013-04-17 2016-03-01 Pfizer Derivados de n-piperidin-3-ilbenzamida para tratar enfermedades cardiovasculares.
CN103739547B (zh) * 2014-01-03 2015-09-02 沈阳药科大学 2-[6-甲氧基-3-(2,3-二氯苯基)甲基-4-氧代-1,4-二氢-1(4h)-喹啉基]乙酸的合成方法
WO2016055901A1 (en) 2014-10-08 2016-04-14 Pfizer Inc. Substituted amide compounds
JP2018511616A (ja) * 2015-04-14 2018-04-26 ケース ウエスタン リザーブ ユニバーシティ 短鎖デヒドロゲナーゼ活性を調節する組成物および方法
WO2017168174A1 (en) 2016-04-02 2017-10-05 N4 Pharma Uk Limited New pharmaceutical forms of sildenafil
SI3352754T1 (sl) 2016-06-21 2021-03-31 The Trustees Of Columbia University In The City Of New York Zaviralci aldozne reduktaze in postopki njihove uporabe
WO2018002673A1 (en) 2016-07-01 2018-01-04 N4 Pharma Uk Limited Novel formulations of angiotensin ii receptor antagonists
WO2018058109A1 (en) * 2016-09-26 2018-03-29 Nusirt Sciences, Inc. Compositions and methods for treating metabolic disorders
WO2018102552A1 (en) 2016-11-30 2018-06-07 Case Western Reserve University Combinations of 15-pgdh inhibitors with corcosteroids and/or tnf inhibitors and uses thereof
JP2020514323A (ja) 2017-02-06 2020-05-21 ケース ウエスタン リザーブ ユニバーシティ 短鎖デヒドロゲナーゼ活性を調節する組成物と方法
IL272246B1 (en) 2017-07-28 2025-09-01 Applied Therapeutics Inc Derivatives of 2-(4-oxo/thioketone/azo-3-((substituted)benzo[d]thiazol-2-yl)methyl)- 3,4-dihydrothieno[3,4-d]pyridazin-1-yl)acetic acid for use as aldose reductase inhibitors in treating galactosemia or preventing complications associated with galactosemia
EA202191422A1 (ru) 2018-11-21 2021-10-21 Кейс Вестерн Ризерв Юниверсити Композиции и способы модулирования активности короткоцепочечной дегидрогеназы
DK3911648T3 (da) 2019-01-18 2025-01-13 Astrazeneca Ab 6'-[[(1s,3s)-3-[[5-(difluormethoxy)-2-pyrimidinyl]amino]cyclopentyl]amino][1(2h),3'-bipyridin]-2-on som pcsk9-hæmmer og fremgangsmåder til anvendelse deraf
CN113966396A (zh) 2019-05-07 2022-01-21 迈阿密大学 遗传性神经病和相关障碍的治疗和检测
KR20220034739A (ko) 2019-05-31 2022-03-18 이케나 온콜로지, 인코포레이티드 Tead 억제제 및 이의 용도
KR20220030222A (ko) 2019-05-31 2022-03-10 이케나 온콜로지, 인코포레이티드 Tead 억제제 및 이의 용도
WO2022120353A1 (en) * 2020-12-02 2022-06-09 Ikena Oncology, Inc. Tead inhibitors and uses thereof

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IE47592B1 (en) 1977-12-29 1984-05-02 Ici Ltd Enzyme inhibitory phthalazin-4-ylacetic acid derivatives, pharmaceutical compositions thereof,and process for their manufacture
US4939140A (en) 1985-11-07 1990-07-03 Pfizer Inc. Heterocyclic oxophthalazinyl acetic acids
US4996204A (en) 1989-05-11 1991-02-26 Pfizer Inc. Pyrido[2,3-d]pyridazinones as aldose reductase inhibitors
FR2647676A1 (fr) 1989-06-05 1990-12-07 Union Pharma Scient Appl Nouveaux derives de pyridazinone, leurs procedes de preparation, medicaments les contenant, utiles notamment comme inhibiteurs de l'aldose reductase
EP0516860A4 (en) * 1990-11-30 1993-12-01 Tsumura & Co. Chromone derivative and aldose reductase inhibitor containing the same as active ingredient
CZ387092A3 (en) 1991-03-28 1994-02-16 Pfizer Pyridazinoacetic acids, their derivatives, process of their preparation and use
US5834466A (en) 1994-12-22 1998-11-10 The Regents Of The University Of California Method for protecting of heart by limiting metabolic and ionic abnormalities developed during ischemia, following ischemia or resulting from ischemia
TWI238064B (en) 1995-06-20 2005-08-21 Takeda Chemical Industries Ltd A pharmaceutical composition for prophylaxis and treatment of diabetes
WO1999015523A1 (en) * 1997-09-24 1999-04-01 Orion Corporation Bisethers of 1-oxa, aza and thianaphthalen-2-ones as phospholamban inhibitors
FR2822827B1 (fr) * 2001-03-28 2003-05-16 Sanofi Synthelabo Nouveaux derives de n-(arylsulfonyl) beta-aminoacides comportant un groupe aminomethyle substitue, leur procede de preparation et les compositions pharmaceutiques en contenant
YU71403A (sh) * 2001-03-30 2006-05-25 Pfizer Products Inc. Piridazinoni kao inhibitori aldoza reduktaze
PL367112A1 (en) * 2001-04-30 2005-02-21 Pfizer Products Inc. Combinations of aldose reductase inhibitors and cyclooxygenase-2 inhibitors
CN1269814C (zh) * 2002-01-09 2006-08-16 辉瑞产品公司 哒嗪酮抗糖尿病药的制备方法和中间体

Also Published As

Publication number Publication date
WO2002079198A1 (en) 2002-10-10
IS6845A (is) 2003-06-16
EP1491541A1 (en) 2004-12-29
AR035798A1 (es) 2004-07-14
CN1215067C (zh) 2005-08-17
IL156462A0 (en) 2004-01-04
EP1491541B1 (en) 2007-01-24
UY27237A1 (es) 2002-12-31
KR100586138B1 (ko) 2006-06-07
SK11852003A3 (sk) 2004-07-07
SI1373259T1 (en) 2005-04-30
US20020143017A1 (en) 2002-10-03
ATE286049T1 (de) 2005-01-15
ATE348100T1 (de) 2007-01-15
ES2274369T3 (es) 2007-05-16
IS2205B (is) 2007-02-15
OA12453A (en) 2006-05-24
EP1491540A1 (en) 2004-12-29
MA27003A1 (fr) 2004-12-20
ZA200304671B (en) 2004-06-25
HUP0303644A2 (hu) 2004-03-01
DE60202452T2 (de) 2006-02-09
MXPA03008850A (es) 2003-12-04
DE60202452D1 (de) 2005-02-03
YU71403A (sh) 2006-05-25
NZ528406A (en) 2004-03-26
PE20030007A1 (es) 2003-01-28
DE60202452C5 (de) 2006-11-23
EP1373259B1 (en) 2004-12-29
DE60217930T2 (de) 2007-10-18
IS8251A (is) 2006-01-23
ATE352551T1 (de) 2007-02-15
JP2004528319A (ja) 2004-09-16
PA8541801A1 (es) 2002-10-28
GEP20053675B (en) 2005-11-25
EP1491540B1 (en) 2006-12-13
NO20034345D0 (no) 2003-09-29
ECSP034671A (es) 2003-08-29
US6579879B2 (en) 2003-06-17
TWI245762B (en) 2005-12-21
EA006023B1 (ru) 2005-08-25
EA200300673A1 (ru) 2003-12-25
AP2002002461A0 (en) 2002-06-30
DK1491540T3 (da) 2007-03-26
KR20030088484A (ko) 2003-11-19
MY134304A (en) 2007-12-31
PL365294A1 (en) 2004-12-27
DE60217930D1 (de) 2007-03-15
TNSN02037A1 (fr) 2005-12-23
CN1500087A (zh) 2004-05-26
EE200300470A (et) 2004-02-16
AU2002226634B2 (en) 2007-01-25
DE60216823T2 (de) 2007-10-04
IS8250A (is) 2006-01-23
PT1491540E (pt) 2007-01-31
BG108179A (en) 2004-09-30
NO20034345L (no) 2003-09-29
DE60216823D1 (de) 2007-01-25
US6849629B2 (en) 2005-02-01
HRP20030752A2 (en) 2005-06-30
CA2442476A1 (en) 2002-10-10
PT1373259E (pt) 2005-03-31
HUP0303644A3 (en) 2008-06-30
HK1061678A1 (en) 2004-09-30
EP1373259A1 (en) 2004-01-02
ES2231681T3 (es) 2005-05-16
US20030162784A1 (en) 2003-08-28
UA73236C2 (en) 2005-06-15
BR0208571A (pt) 2004-03-23
CZ20032563A3 (cs) 2004-05-12

Similar Documents

Publication Publication Date Title
DK1373259T3 (da) Pyridazinonaldosereduktaseinhibitorer
DE60234125D1 (de) E inhibitoren
CY2015028I1 (el) Ενας αναστολεας ν-ακυλοσφιγγοσινο γλυκοζυλοτρανσφερασης
PT1370553E (pt) Inibidores de rhoquinase
DK1223918T3 (da) Farmaceutiske præparater omfattende en HMG-CoA-reductaseinhibitor
DE60218138D1 (de) Rho-kinase inhibitoren
NO20034042D0 (no) Metallproteinase-inhibitorer
ATE397925T1 (de) Cis-imidazoline als mdm2-hemmer
ATE505471T1 (de) Azaindol-kinaseinhibitoren
IS7138A (is) Alkýn-arýl fosfódíesterasa-4 hindrar
EE200300439A (et) Metalloproteinaasi inhibiitorid
ATE420640T1 (de) Fab-i-inhibitoren
DE50303193D1 (de) Übertrager
NO20034032D0 (no) Metallproteinase-inhibitorer
DK1272488T3 (da) Tri-aryl-substitueret ethan-PDE4-inhibitorer
DE60110029D1 (de) Papierzuführwalze
EP1463521A4 (en) INHIBITOR OF GP41
NO20013535L (no) Nöytrofil-funksjons-inhibitorer
ITMI20010954A0 (it) Procedimento di iodurazione
DE60229669D1 (de) X-2 inhibitoren
DE50209548D1 (de) Substituierte 1-aryl-but-3-enylamin- und 1-aryl-but-2-enylaminverbindungen
DE50115802D1 (de) Dafür
SE0100694D0 (sv) DHFR inhibitors
ITMI20011624A0 (it) Timpano di tompagnatura
FI5322U1 (fi) Kulmaosa